Clinical Trial

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Name: Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma — clinical trial record (NCT07283731)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Protocol Amendment History 1 change

critical Trial status changed: Not Yet Recruiting → Suspended 2026-04-07

Trial Details

NCT Number	NCT07283731
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Exelixis
Conditions	Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
Enrollment	20 participants
Start Date	2026-06-02
Primary Completion	2028-11-01 (estimated)
Study Completion	2030-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-17